L Capital Partners

Elemé Medical, Inc. is a venture backed aesthetics company dedicated to providing market-leading technology in all areas of body shaping. The newly launched SmoothShapes® XV will revolutionize how cellulite is treated and introduce exciting new protocols for pre and post liposuction care. With 50% more laser power, SmoothSpeed™ audible & visual treatment guidance and a portable, sleek console design, SmoothShapes XV is an ideal way to add non-invasive body shaping to a practice. SmoothShapes XV is the newest product launched by the Company and joins the original SmoothShapes launched in 2008, both products are a CE Marked, FDA-cleared medical devices for the temporary reduction in the appearance of cellulite. Both SmoothShapes systems are based on the company's proprietary Photomology® platform – a process that treats cellulite and subcutaneous fat by combining dynamic light and laser energy along with mechanical manipulation (vacuum and massage). The system addresses the physical manifestations of cellulite and its underlying causes providing long lasting results that patients can see and feel. Targets include plastic surgeons, aesthetic dermatologists, medical spas and other aesthetic physicians. According to Global Body Shaping Market Analysis, body shaping is one of the top growth areas in the Aesthetics market with 19% growth through the year 2012. The global aesthetics market is projected to grow from $5.0 billion in 2008 to $8.1 billion by 2011.

CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

IntraPace® has developed a novel implantable system to treat obesity. It is built on the proven technology used in millions of cardiac pacemakers and defibrillators each year. The abiliti® system is designed to be implanted via standard laparoscopic instruments without making any changes to the anatomy of the digestive system or placing any limitations on what a person can eat or drink.

Locus Pharmaceuticals, Inc. engages in developing novel and small molecule therapeutic drugs to address major unmet medical needs. The company has a computational drug design technology, which is used to develop a pipeline of drug development candidates, including direct and allosteric kinase inhibitors for cancer and inflammation diseases. Locus Pharmaceuticals, Inc. was formerly known as Locus Discovery, Inc. and changed its name to Locus Pharmaceuticals, Inc. in January 2003. The company was incorporated in 1998 and is based in Blue Bell, Pennsylvania. Locus Pharmaceuticals, Inc. is a former subsidiary of Sarnoff Corporation.

Evogen, Inc. provides air sampling solutions. Its air samplers, detectors, and detection validation technology is used for military, homeland security, commercial, government, and civilian environments in United States. It offers OMNI 3000, an aerosol sampler for indoor/outdoor applications; integrated detection system, a solution for biological threat detection; and SpinCon, an aerosol collection technology for biological and certain chemical systems. The company also offers specially manufactured consumables and accessories. Its solutions are used for various applications, such as postal security, homeland security, facility security, incident response, operations security, disaster recovery, disease detection, and warfighter protection. The company was founded as Sceptor Industries, Inc. in 2001 and changed its name to Evogen, Inc. in August 2008. The company is based in Kansas City, Missouri.

WiSpry, Inc. develops fabless radio frequency semiconductor. It offers tunable RF components, digital capacitor arrays, RF evaluation kits, filters and duplexors, and power amplifiers. The company’s products are used in airbag sensors, game controllers, accelerometers, microoptics, video projection systems, and printer heads. It serves mobile handset manufacturers and network operators. The company was founded in 2002 and is based in Irvine, California. As of May 7, 2015, WiSpry, Inc. operates as a subsidiary of AAC Technologies Holdings Inc.

CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

The El Ganso style is composed of a cosmopolitan look tinged with Spanish colours and ranges from preppy American looks to the more alternative Berlin style, via a touch of English elegance. Its signature, classic and cheeky, has become the main emblem of the brand, an inspiration that can be observed in the optimism of its garments, footwear and accessories. The originality and strength of its designs can be easily recognized in the taste for details and fabrics. Every collection is designed and manufactured 100% within Europe from local raw materials in accordance with the company’s main priorities of design, quality and innovation.

Hi-G-Tek is the developer of a new active-RFID platform for real-time monitoring and control of critical physical assets. Their company is commercializing patented technology that enables low power, cost-effective wireless solutions for monitoring, assessing and protecting high-value physical assets and sensitive materials. Their unique solutions provide unprecedented levels of real-time security and “sensing” of key assets, whether stationary or in transit, indoors or outdoors.

Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.

Switchfly is a global technology company that powers travel commerce, loyalty program engagement and ancillary product offerings for some of the world’s most recognizable brands. Leading airlines, hotels, online travel agencies and financial service providers depend on Switchfly to power their omni-channel travel experiences because it uniquely combines a highly scalable and secure architecture with deep product and content inventory.

iScience Interventionalâ„¢ discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific ocular therapies. This new category of therapy is called Interventional Ophthalmology. It encompasses microcatheter-based therapies designed to access a wide range of anatomical structures within the eye to aspirate ocular fluids or deliver sterile ophthalmic solutions to the eye.

Cigierre develops, operates, and manages multiethnic restaurants.

CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

WiSpry, Inc. develops fabless radio frequency semiconductor. It offers tunable RF components, digital capacitor arrays, RF evaluation kits, filters and duplexors, and power amplifiers. The company’s products are used in airbag sensors, game controllers, accelerometers, microoptics, video projection systems, and printer heads. It serves mobile handset manufacturers and network operators. The company was founded in 2002 and is based in Irvine, California. As of May 7, 2015, WiSpry, Inc. operates as a subsidiary of AAC Technologies Holdings Inc.

Hi-G-Tek is the developer of a new active-RFID platform for real-time monitoring and control of critical physical assets. Their company is commercializing patented technology that enables low power, cost-effective wireless solutions for monitoring, assessing and protecting high-value physical assets and sensitive materials. Their unique solutions provide unprecedented levels of real-time security and “sensing” of key assets, whether stationary or in transit, indoors or outdoors.

WiSpry, Inc. develops fabless radio frequency semiconductor. It offers tunable RF components, digital capacitor arrays, RF evaluation kits, filters and duplexors, and power amplifiers. The company’s products are used in airbag sensors, game controllers, accelerometers, microoptics, video projection systems, and printer heads. It serves mobile handset manufacturers and network operators. The company was founded in 2002 and is based in Irvine, California. As of May 7, 2015, WiSpry, Inc. operates as a subsidiary of AAC Technologies Holdings Inc.

Vicini develops and manufactures footwear for men and women. The company sells its products through its Milan and New York showrooms to a selected clientele, and to its boutiques. It also offers its products through stores in Europe, Russia, Asia, and Australia.

IntelliPath Solutions provides Information Management consulting services to companies who leverage data as an asset of their organization. IntelliPath’s industry experience in both IT and business, in combination with our ability to align innovation and best practices, allows for successful partnerships with our clients.

Your business is growing quickly, but things on the manufacturing side are disconnected and unknown. Exenta, Inc. Shopfloor 3PMTM brings real-time visibility and control to the forefront. Timing : Mon - Fri 09:00 AM to 06:00 PM, Sat - Sun - Closed Address : 8 W 38th St, New York, NY 10018

Protez Pharmaceuticals is a medical research company that discovers, develops, and commercializes antibiotics for difficult-to-treat hospital-based infections. The company focuses on differentiated intravenous and oral small molecule antibiotics to address bacterial resistant, and chronic or recurrent infections. Protez Pharmaceuticals was founded by Christopher M. Cashman in 2003 and is headquartered in Malvern, Pennsylvania.